US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Mirati Therapeutics Inc
NASDAQ:MRTX
Mirati Therapeutics Inc
Cash & Cash Equivalents
Mirati Therapeutics Inc
Cash & Cash Equivalents Peer Comparison
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Mirati Therapeutics Inc
NASDAQ:MRTX
|
Cash & Cash Equivalents
$258.7m
|
CAGR 3-Years
25%
|
CAGR 5-Years
17%
|
CAGR 10-Years
43%
|
|
Abbvie Inc
NYSE:ABBV
|
Cash & Cash Equivalents
$18.1B
|
CAGR 3-Years
23%
|
CAGR 5-Years
30%
|
CAGR 10-Years
8%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash & Cash Equivalents
$4.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-3%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash & Cash Equivalents
$9.7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash & Cash Equivalents
$9.2B
|
CAGR 3-Years
13%
|
CAGR 5-Years
26%
|
CAGR 10-Years
36%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash & Cash Equivalents
$2.6B
|
CAGR 3-Years
22%
|
CAGR 5-Years
9%
|
CAGR 10-Years
19%
|
See Also
What is Mirati Therapeutics Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
258.7m
USD
Based on the financial report for Sep 30, 2023, Mirati Therapeutics Inc's Cash & Cash Equivalents amounts to 258.7m USD.
What is Mirati Therapeutics Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
43%
Over the last year, the Cash & Cash Equivalents growth was -13%. The average annual Cash & Cash Equivalents growth rates for Mirati Therapeutics Inc have been 25% over the past three years , 17% over the past five years , and 43% over the past ten years .